OPTIMISING THE PATHOGENETIC TREATMENT OF CERVICAL OCCLUSION
Scientific clinical research
Versandkostenfrei!
Versandfertig in 6-10 Tagen
39,99 €
inkl. MwSt.
PAYBACK Punkte
20 °P sammeln!
Based on the studies performed by the author, a new pathogenetically based approach to achieve effective and safe treatment of central retinal vein occlusion was proposed, which is of great theoretical and practical importance for ophthalmology. The efficacy of a single intravitreal injection of recombinant tissue plasminogen activator (rTAP, Actilyse) in a dose of 50 mcg in the treatment of patients with retinal vein thrombosis not more than 7 days old has been established. The best effect is observed when this treatment is combined with the endothelioprotector Wessel Due F. The indicated the...
Based on the studies performed by the author, a new pathogenetically based approach to achieve effective and safe treatment of central retinal vein occlusion was proposed, which is of great theoretical and practical importance for ophthalmology. The efficacy of a single intravitreal injection of recombinant tissue plasminogen activator (rTAP, Actilyse) in a dose of 50 mcg in the treatment of patients with retinal vein thrombosis not more than 7 days old has been established. The best effect is observed when this treatment is combined with the endothelioprotector Wessel Due F. The indicated therapy leads to rapid recanalisation of the thrombosed vein, resorption of intraretinal haemorrhages and partial resorption of macular edema. The work proves that the parameters of the plasma-coagulation link of the hemostasis system are normalized considerably and the activity of the fibrinolytic system increases in the course of treatment. The proposed use of these drugs reduces the risk of complications of thrombolytic therapy as well as the disease itself - retinal vein thrombosis.
Andere Kunden interessierten sich für
